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Abstract
AIM: To evaluate the association between the severity of
liver steatosis and metabolic syndrome in apparently
healthy Korean adults.
METHODS: We examined 1 022 men and women, aged
30-79 years, who participated in a health screening test.
A standard interview, anthropometrics, biochemical studies,
and abdominal ultrasonography were conducted for each
participant. Metabolic syndrome was defined according
to the National Cholesterol Education Program Adult
Treatment Panel III, with a modification for the waist
circumference cut-off level. The severity of liver steatosis
was evaluated using liver ultrasonography, and serum
aspartate aminotransferase (AST), alanine aminotransferase
(ALT), and γ-glutamyl transferase (γ-GT) levels were
determined.
RESULTS: Ultrasonographic liver steatosis was strongly
associated with metabolic syndrome and common
metabolic abnormalities. Compared with people without
steatosis, people with mild, moderate, and severe steatosis
had adjusted odds ratios for metabolic syndrome of 1.72
(95%CI, 1.01-2.94), 2.89 (1.75-4.76) and 3.53 (1.25-9.98)
in men, and 2.86 (1.64-5.01), 3.19 (1.80-5.65) and 3.70
(0.82-16.73) in women, respectively. The serum AST level
was not associated with metabolic syndrome. The serum
ALT and γ-GT levels were significantly associated with
metabolic syndrome in men but not in women.
CONCLUSION: The occurrence of metabolic syndrome
shows a stronger association with the severity of
ultrasonographic steatosis than with the serum liver
enzyme levels. The degree of fatty infiltration detected
on ultrasonography can be used as an indicator of liver
dysfunction attributable to metabolic abnormalities.
© 2005 The WJG Press and Elsevier Inc. All rights reserved.
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INTRODUCTION
Non-viral non-alcoholic fatty liver disease (NAFLD) is an
increasingly recognized condition that accompanies an
increase in obesity[1-3]. NAFLD is known to be associated with
various metabolic abnormalities including central obesity,
type 2 diabetes, dyslipidemia, and high blood pressure[2,4-9],
which are also well-established cardiovascular risk factors.
Recently, it was suggested that fatty liver disease can be
considered to be the hepatic consequence of metabolic
syndrome or of a cluster of metabolic disorders[10-14]. In a
previous report, we showed that NAFLD is closely associated
with various metabolic abnormalities even in non-obese non-
diabetic Korean people[15].
NAFLD has a wide clinical spectrum, and its severity
can be measured by several methods. Liver biopsy represents
the best diagnostic test for staging liver steatosis, inflammation,
and fibrosis, but medical and ethical considerations limit its
use in subjects with non-progressive fatty liver conditions[14,16].
The severity of fatty liver disease can also be evaluated
based on the serum levels of liver enzymes such as aspartate
aminotransferase (AST), alanine aminotransferase (ALT),
and γ-glutamyl transferase (γ-GT)[1,2]. These enzymes are
sensitive markers of liver cell damage, but they cannot
provide information on the underlying causes of  that
damage. It has been shown that liver ultrasonography,
although not sufficiently sensitive to detect liver inflammation
and fibrosis, demonstrates a good correlation with histological
findings of fatty infiltration, and international guidelines have
been proposed for the diagnosis of different degrees of
steatosis[17-19]. However, there are few data available on the
association of metabolic syndrome with the severity of liver
steatosis assessed by ultrasonography.
Therefore, in the present study, we expanded our
investigation to examine the sex-specific association between
the severity of ultrasonographic liver steatosis and the
presence of metabolic syndrome. In addition, we also
examined the sex-specific association between the serum
liver enzyme levels and metabolic syndrome.
MATERIALS AND METHODS
Subjects
This study was performed as part of  the Korean metabolic
syndrome study, which was undertaken to evaluate the role
of metabolic syndrome as a risk factor for cardiovascular
disease in Korean adults. We measured the metabolic
profile, evaluated the cardiovascular risk factors, and
performed abdominal ultrasonography scans on 1 244 men
and women. The measurements were made over a 3-mo
period (April-June, 2001) at a health screening center in
Seoul, South Korea. All participants were healthy,
independently functioning individuals who visited the
health center for health-screening tests. From among
the 1 244 initial volunteers, we selected 1 142 people who
were between 30 and 79 years and who had completed
anthropometric measurements, serum biochemistry
profiles, and liver ultrasonography. We excluded 120 people
who had a previous history of coronary heart disease or
stroke and 35 people who tested positive for hepatitis B
virus surface antigen (HBsAg). Ultimately 1 022 subjects
(557 men and 465 women) were included in the analyses.
Measurements
Trained nurses interviewed all participants and obtained their
medical history, family history of chronic disease, and infor-
mation on life style factors, using a standardized questionnaire.
The weight and height of each participant were measured
while the participant was clothed only in a light gown, and
the body mass index was calculated as body weight divided
by height squared (kg/m2). The waist circumference was
measured midway between the lowest rib margin and the
iliac crest in a standing position, by the same examiner. The
percent body fat was measured by bioelectrical impedance
analysis (Inbody 2.0, Biospace Co., South Korea). The
participants were required to rest for at least 5 min prior to
two repeated measurements of their blood pressure at an
interval of  at least 1 min. The mean value of  these two
measurements was used for the analyses. Blood samples
were obtained from each participant after a fasting period
of at least 8 h. The blood glucose level was measured using
the glucose oxidase method. The serum insulin level was
measured using a radioimmunoassay that had an interassay
coefficient of variation of 4%. As an index of insulin
resistance, we used the fasting insulin-glucose product. When
divided by 22.5, this product is numerically equivalent to
the homeostasis model assessment of insulin resistance
(HOMA-IR)[20], which has been shown to correlate well with
the results of the euglycemic hyper-insulinemic clamp in
population-based studies[21]. Serum total cholesterol, high-
density lipoprotein (HDL) cholesterol, and triglyceride levels
were measured on an autoanalyzer using enzymatic colorimetry.
Serum levels of  AST, ALT, and γ-GT were also measured
using enzymatic methods.
The carotid arteries were evaluated by the same examiner
using high-resolution B-mode ultrasonography with a 7.5-
MHz probe. The carotid intima-media thickness (IMT) was
obtained by measuring the distance between the first and
second echogenic lines using a caliper. For each common
carotid artery, three measurements were performed and
the maximum IMT of each common carotid artery was
selected. All measurements were made by the same examiner.
Liver ultrasound scans were performed to assess the
presence and degree of liver steatosis. All ultrasound scans
were performed by the same operator, who was unaware
of the participants’ medical histories and laboratory findings,
using a high resolution B-mode scanner (SSD-5500, Aloka,
Tokyo, Japan). Liver steatosis was assessed semi-quantitatively
on a scale of 0-3 (0, absent; 1, mild; 2, moderate; 3, severe),
on the basis of  abnormally intense, high-level echoes arising
from the hepatic parenchyma, liver-kidney difference in
echo amplitude, echo penetration into the deep portion of
the liver, and clarity of the blood vessel structure in the
liver (Figure 1)[17].
Metabolic syndrome was defined according to the criteria
established by the National Cholesterol Education Program
Adult Treatment Panel III (ATP III), except for the
determination of  abdominal obesity by waist circumference[22].
We used a waist circumference cut-off  level of  >90 cm in
men and >80 cm in women, based on the report by the
International Diabetes Institute/Western Pacific World
Health Organization/International Obesity Task Force[23].
Hence, in this study, participants having three or more of
the following five criteria were defined as having metabolic
syndrome: high blood pressure ( 130/85 mmHg), elevated
fasting blood glucose ( 110 mg/dL or 6.05 mmol/L),
hypertriglyceridemia ( 150 mg/dL or 1.65 mmol/L), low
HDL-cholesterol (men, <40 mg/dL or 1.05 mmol/L;
women, <50 mg/dL or 1.30 mmol/L), and abdominal obesity
by waist circumference (men, >90 cm; women, >80 cm).
Participants taking anti-hypertensive or anti-diabetic medications
were included in the high blood pressure group and the
high fasting blood glucose group, respectively.
Statistical analysis
We reported the clinical and biochemical characteristics of
the participants according to the severity of the liver steatosis
on ultrasound examination, separating the data for the men
and women. For each variable, the linear trend with the
severity of ultrasound liver steatosis was tested. The prevalence
of  abnormal metabolic conditions and metabolic syndrome
were calculated for each level of severity of liver steatosis,
and the linear trends were also tested. In order to assess the
independent association between liver steatosis and
metabolic syndrome, age- and multivariate-adjusted logistic
regression models were used. First, we estimated the age-
adjusted odds ratios of having metabolic syndrome for each
level of severity of liver steatosis. In the multivariate model,
we estimated the corresponding odds ratios after adjustments
for age, menopause (women only), body mass index, cigarette
smoking, and alcohol intake. We also estimated the adjusted
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odds ratios of having metabolic syndrome for the different
levels of  the serum liver enzymes, AST, ALT, and γ-GT.
For each enzyme, four categories were established using
cut-off  values determined by the level at which the number
of individuals in each category was nearest to the number
in the corresponding level of ultrasonographic severity. The
SAS System version 8.01 (SAS Institute, Cary, NC, USA)
was used to perform all statistical analyses. All statistical
tests were two-sided, and P-values less than 0.05 were
considered statistically significant.
RESULTS
Among the 557 men and 465 women examined, ultrasonographic
scans revealed mild steatosis in 133 (23.9%) men and 87
(18.7%) women, moderate steatosis in 165 (29.6%) men
and 93 (20.0%) women, and severe steatosis in 19 (3.4%)
men and 10 (2.2%) women. The clinical characteristics and
laboratory data of the participants with different degrees
of steatosis as detected on ultrasonography are shown in
Table 1. In men, the mean age was similar among the groups
with different severities of steatosis, but in women there
was a positive association between age and liver steatosis.
With increasing severity of liver steatosis, there were
statistically significant progressive increases in mean body
mass index, waist circumference, body fat percent, blood
pressure, total serum cholesterol, and serum triglycerides,
and there was a statistically significant decrease in mean
HDL-cholesterol. A statistically significant increase was also
observed in the mean fasting glucose and insulin levels, and
in insulin resistance, as assessed by mean HOMA values.
The levels of  liver enzymes (AST, ALT, and γ-GT) and
carotid IMT were also positively associated with the degree
of fatty infiltration. In contrast, cigarette smoking and alcohol
intake were not associated with liver steatosis.
In both men and women, fatty liver detected by
ultrasonography was strongly associated with metabolic
syndrome and the five metabolic abnormalities, which are
criteria for its clinical diagnosis. Among the 515 people
without liver steatosis, only 19.6% (16.3% for men and
22.6% for women) had metabolic syndrome, whereas
almost half (48.3%; 41.0% for men and 60.5% for women)
of those with liver steatosis had metabolic syndrome. In
addition, the prevalence of metabolic syndrome and of
each of  the five metabolic abnormalities progressively
increased with the severity of  liver steatosis (Table 2).
In the age-adjusted logistic regression model, the
participant group with liver steatosis had a significantly higher
odds ratio of having metabolic syndrome than did the group
without steatosis. The odds ratio also increased with
increasing severity of liver steatosis. When we adjusted for
age, menopause, body mass index, cigarette smoking and
alcohol intake, the association between liver steatosis and
metabolic syndrome was attenuated but still was highly
significant (Table 3). To assess the possible confounding effects
of alcoholic hepatitis, we examined the association between
liver steatosis and metabolic syndrome by frequency of
alcohol intake and found similar results regardless of the
frequency of alcohol consumption (data not shown).
The possible associations of  serum levels of  AST, ALT,
and γ-GT with metabolic syndrome were also examined.
The serum AST level was not significantly associated with
metabolic syndrome in either sex. Serum ALT and γ-GT
levels were significantly associated with metabolic syndrome
in men but not in women (Table 4).
DISCUSSION
Metabolic syndrome is very common in Western countries
and is also increasingly frequent in most developing countries.
Fatty liver is a common condition increasingly detected by
Figure 1  Ultrasonographic findings of liver according to the degree of steatosis. (A) Normal liver, (B) mild steatosis: a slight augmentation in liver echogenicity, a
slight exaggeration of echogenic discrepancy between liver and kidney, and a relative preservation of echo line in the portal vein wall. (C) Moderate steatosis: a loss
of echo line in the portal vein wall, particularly from the peripheral branches, resulting in a featureless appearance of the liver. (D) Severe steatosis: much greater
reduction in echo penetration, a loss of echogenicity in most of the portal vein wall, including the main branches, and a large echo discrepancy between liver and
kidney. Adapted from Saverymuttu et al.[17].
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routine abdominal ultrasonographic examination; however,
the spectrum of fatty liver varies from mild NAFLD to
progressive non-alcoholic steatohepatitis (NASH). NAFLD is
a benign fatty liver disease, which accounts for the majority of
elevated aminotransferase levels in asymptomatic patients[24].
In contrast, NASH is a more progressive form of  fatty
liver disease that can progress to liver fibrosis and even
cirrhosis[1,14,25]. It has been suggested that fatty liver develops
as the result of various metabolic conditions that promote
fat accumulation and inflammation in the liver[10-14].
Liver biopsy is the only diagnostic test that is able to
differentiate benign NAFLD from progressive NASH, but
Table 1  Clinical and biochemical characteristics of 557 men and 465 women with different severities of ultrasonographic liver steatosis
         Ultrasonographic liver steatosis
   Men                Women
Characteristics          P for trend                             P for trend
 Absent           Mild             Moderate         Severe                          Absent    Mild             Moderate         Severe
                   (n = 240)        (n = 133)         (n = 165)           (n = 19)      (n = 275) (n = 87)               (n = 93)        (n = 10)
Age (yr)                   51.6±11.0       50.0±9.9         51.4±10.6    49.2±11.2          0.521      51.5±9.4              52.7±9.5              55.5±7.8        55.9±9.1           <0.001
Body mass index (kg/m2)    23.1±2.5       24.7±2.3         25.3±2.6    26.5±2.1          <0.001      23.6±2.7              25.8±3.1              26.6±3.0        27.5±4.0           <0.001
Waist circumference (cm)     83.0±6.9        88.0±6.5         89.2±6.3    92.1±6.8          <0.001      79.0±7.0              85.2±7.7              88.0±7.4        88.5±8.5           <0.001
Body fat percent                   20.0±4.4       23.0±4.2         23.4±4.1    24.1±3.5          <0.001      30.1±4.7              33.2±5.4              34.8±4.9        36.1±3.8           <0.001
Systolic BP (mmHg)            126.7±16.9     129.4±16.0     133.9±18.8  133.7±10.7       <0.001    128.4±20.2         131.7±17.3            136.5±19.1     138.5±10.6         <0.001
Diastolic BP (mmHg)            78.2±11.5       79.9±11.1       83.0±12.2    84.2±7.9          <0.001      78.2±13.2            80.7±12.0              82.7±11.9        82.0±7.9 0.002
Total cholesterol                194.5±32.2     200.6±33.4     205.3±34.6     204.7±25.1         0.001    201.3±33.0         208.3±37.3           217.0±36.9     225.4±28.2         <0.001
(mg/dL)
Triglyceride (mg/dL)        149.4±104.9  200.2±119.5  230.1±161.8  230.6±111.7     <0.001    123.5±93.1         164.5±115.3         188.6±122.0      184.0±80.1         <0.001
HDL-cholesterol                   46.2±10.4       43.7±9.6         41.3±8.3     41.7±8.8          <0.001      52.9±13.4            47.3±12.8             47.0±12.1       47.0±7.6            <0.001
(mg/dL)
Fasting glucose                   97.5±23.3    101.7±19.6    108.3±29.4  117.2±36.0        <0.001      92.7±21.2         102.9±36.3            103.4±27.4     109.7±17.7         <0.001
(mg/dL)
Fasting insulin (IU/L)  9.8±11.4       11.9±6.9         12.6±7.1     13.2±5.1             0.002         9.1±4.9               13.9±8.6              15.1±9.7        16.9±6.2           <0.001
HOMA-IR   2.6±5.4           3.0±1.9           3.3±2.0       3.9±1.8              0.037         2.1±1.4   3.5±2.3                3.8±2.5          4.5±1.5           <0.001
AST (IU/L)                   22.4±7.2        25.0±10.0       27.5±21.5     29.5±8.0          <0.001      21.0±7.8               21.4±11.3             23.0±11.2       28.2±6.3              0.013
ALT (IU/L)                   23.4±11.8       31.5±18.3      38.3±35.9     50.8±19.0       <0.001      19.2±13.5            21.8±13.8             26.8±17.4       34.8±12.9         <0.001
γ-GT (IU/L)                   45.1±50.6       67.1±63.4      69.4±148.8     69.4±42.6           0.009      23.7±22.8            31.6±37.7             32.8±21.3       38.7±11.1         <0.001
Carotid IMT (mm)                  0.71±0.19        0.75±0.21      0.79±0.26     0.73±0.13        <0.001       0.70±0.21           0.77±0.23              0.79±0.23        0.81±0.31         <0.001
Menopause (%)            58.2      60.9 81.5             90.0              <0.001
Current smoking     47.9             46.6  42.4          42.1                0.269              5.1      5.8    1.1             10.0 0.345
Alcohol intake 4/wk     55.6             60.9  53.0          42.1                0.387            13.2      17.2    9.7              - 0.314
Carotid IMT 1.0 (mm)     10.0             10.5  17.0            5.3                0.143              6.6      12.6    8.6             20.0 0.145
Table 2 Sex-specific prevalence of metabolic disorders by the severity of ultrasonographic liver steatosis
              Severity of ultrasonographic liver steatosis
Absent    Mild                  Moderate  Severe    P
Men (%) (n = 240) (n = 133) (n = 165) (n = 19)
    Waist circumference >90 (cm)     14.6     33.1     44.2     57.9                 <0.001
    Blood pressure 130/85 (mmHg)1     51.7     52.6     72.1     84.2                 <0.001
    Fasting glucose 110 (mg/dL)2     11.3     12.0     21.8     15.8                   0.008
    Triglyceride 150 (mg/dL)     33.8     63.2     67.3     73.7                 <0.001
    HDL-cholesterol <40 (mg/dL)     30.4     39.8     42.4     36.8                   0.020
    Metabolic syndrome ( 3 of the above)     16.3     31.6     46.7     57.9                 <0.001
    Number of metabolic  1.4±1.1  2.0±1.2  2.5±1.1  2.7±1.1                 <0.001
    abnormalities, mean±SD
Women (%)  (n = 275) (n = 87) (n = 93) (n = 10)
    Waist circumference >80 (cm)      42.9    81.6    87.1    90.0                 <0.001
    Blood pressure 130/85 (mmHg)1      56.4    64.4    73.1                    100.0                 <0.001
    Fasting glucose 110 (mg/dL)2        2.2    14.9    16.1    40.0                 <0.001
    Triglyceride 150 (mg/dL)      22.9    34.5    47.3    60.0                 <0.001
    HDL-cholesterol <50 (mg/dL)      41.8    62.1    62.4    70.0                 <0.001
    Metabolic syndrome ( 3 of the above)      22.5    54.0    65.6    70.0                 <0.001
    Number of metabolic   1.7±1.1 2.6±1.1 2.9±1.1 3.6±1.3                 <0.001
    abnormalities, mean±SD
HDL: high density lipoprotein. 1Including subjects taking anti-hypertensive medication. 2Including subjects taking anti-diabetic medication.
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it should not be performed on the majority of  patients with
asymptomatic or mild fatty liver disease. Thus, the clinical
evaluation of the severity of fatty liver disease in people
with metabolic syndrome is usually based on a combination
of ultrasonographic findings and laboratory tests. Liver
ultrasonography is frequently used to assess fatty infiltration
of  the liver, but there is little information on the association
between the metabolic diseases and the severity of fatty
liver detected by ultrasonography. One previous study
reported an association between common metabolic disorders
and the severity of liver steatosis assessed by routine
ultrasonography in 340 patients[14]. The present study showed
that various metabolic abnormalities and metabolic syndrome
were positively associated with the severity of ultrasonographic
liver steatosis detected in 1 022 healthy people. Our findings
suggest that liver ultrasonography can be used to monitor
liver dysfunction that occurs in association with common
metabolic abnormalities and metabolic syndrome.
Serum aminotransferase assays have also been widely
used to detect and diagnose NAFLD[2,9], which is the most
common cause of unexplained aminotransferase elevations
in most Western populations and in some Asian populations.
Thus, we assessed the associations between metabolic
syndrome and the levels of several liver enzymes. In our
data, metabolic syndrome showed a significant association
with ALT and γ-GT levels only in men and showed no
significant association with AST levels in either sex. For
purposes of comparison, we categorized the enzyme levels
so that the distribution of participants in the categories was
similar to the distribution of subjects by ultrasonographic
severity of steatosis; however, this type of categorization
would not be relevant in clinical settings. Thus, we performed
further analyses using different classification schemes and
obtained similar findings.
The serum AST level is a sensitive marker of liver cell
damage, but it has been less frequently used than ALT and
γ-GT levels to monitor liver dysfunction because it is
relatively non-specific for liver disease and correlates poorly
with the clinical severity of liver disease[26]. Our findings
support the use of  serum ALT and γ-GT levels as indicators
of the development of liver steatosis in men with metabolic
syndrome. Recently, Jeong and colleagues reported that
serum ALT levels were positively associated with metabolic
disorders in a population, even when the levels were in the
Table 3  Sex-specific associations between the severity of ultrasonographic liver steatosis and metabolic syndrome
Ultrasound               Number                Number with Age-adjusted Multivariate-adjusted
liver steatosis              of people    metabolic syndrome (%) odds ratio (95%CI) odds ratio (95%CI)1
Men
    Absent 240  39 (16.3) 1.00 1.00
    Mild 133  42 (31.6) 2.43 (1.47-4.01) 1.72 (1.01-2.94)
    Moderate 165  77 (46.7) 4.54 (2.87-7.20) 2.89 (1.75-4.76)
    Severe   19  11 (57.9) 7.32 (2.76-19.44) 3.53 (1.25-9.98)
    Total 557                  169 (30.3) P<0.001 P<0.001
Women
    Absent 275  62 (22.6) 1.00 1.00
    Mild   87  47 (54.0) 4.06 (2.41-6.83) 2.86 (1.64-5.01)
    Moderate   93  61 (65.6) 5.81 (3.45-9.80) 3.19 (1.80-5.65)
    Severe   10    7 (70.0) 7.07 (1.73-28.89) 3.70 (0.82-16.73)
    Total 465                  177 (38.1) P<0.001 P<0.001
1Adjusted for age, menopause (in women), body mass index, cigarette smoking, and alcohol intake.
Table 4  Sex-specific associations between liver enzyme levels and metabolic syndrome
AST (IU/L) Multivariate-adjusted ALT (IU/L) Multivariate-adjusted γ-GT (IU/L) Multivariate-adjusted
odds ratio (95%CI)1 odds ratio (95%CI)1 odds ratio (95%CI)1
Men
9-21 1.00 4-22 1.00 9-35 1.00
22-25 0.69 (0.42-1.16) 23-31 1.76 (1.04-2.99) 36-52 1.66 (0.95-2.90)
26-46 0.89 (0.54-1.45) 32-77 2.57 (1.54-4.29) 53-180 3.20 (1.87-5.47)
47-278 1.81 (0.62-5.28) 78-421 5.23 (1.69-16.18) 181-1 885 3.33 (1.09-10.16)
P = 0.953 P<0.001 P<0.001
Women
9-21 1.00 4-19 1.00 8-22 1.00
22-24 0.58 (0.32–1.06) 20-24 1.22 (0.70-2.12) 23-31 1.87 (1.06-3.30)
25-42 0.96 (0.54–1.70) 25-61 1.44 (0.83-2.50) 32-100 1.25 (0.72-2.19)
43-117 0.68 (0.16–2.93) 62-172 0.87 (0.20-3.73) 101-323 1.46 (0.33-6.37)
P = 0.475 P = 0.271 P = 0.230
AST: aspartate aminotransferase; ALT: alanine aminotransferase; γ-GT: γ-glutamyl transferase. 1Adjusted for age, menopause (in women), body mass index, cigarette
smoking, and alcohol intake.
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normal range[27]. The results of  that study differed from
ours in that, the authors found a significant association in
both sexes, although the association in women was weaker
than that in men.
The sex-specific differences in the associations between
liver enzyme levels and metabolic syndrome were not fully
explained by the data. One contributing factor may be that,
compared with men, women have relatively low ALT and
γ-GT levels that fall within relatively narrow ranges[28,29].
Thus, serum enzyme levels in women might show a poor
correlation with liver dysfunction. Another contributing
factor to the sex-specific differences might be that the
underlying causes of the enzyme elevation may differ by
sex. For example, if  central obesity is a major cause of
enzyme elevation in men but not in women, the relationship
between enzyme elevation and metabolic syndrome would
likely differ by sex. Sakugawa et al., reported that serum
γ-GT was correlated with the components of metabolic
syndrome and its risk factors in the univariate analysis, but
four variables were independently associated with γ-GT:
age, hemoglobin, triglyceride, and diabetes[30]. The sex-specific
differences shown by our analysis may also be attributable
to chance observation. Thus, the association between the
serum enzyme levels and metabolic syndrome in women
requires further investigation.
The association between fatty liver disease and metabolic
syndrome may be explained by several mechanisms. Type
2 diabetes (or insulin resistance) and central obesity have
been frequently reported to be associated with both benign
NAFLD and progressive NASH[2,4-9]. Insulin resistance is a
key component of metabolic syndrome and is also a well-
known risk factor for the development of NAFLD[31-33].
However, it is still controversial whether liver disease plays
a primary role in the development of hyper-insulinemia and
insulin resistance or is a consequence of insulin resistance.
Recent studies have added evidence supporting the interpretation
that insulin resistance is the primary phenomenon, by showing
that hyper-insulinemia and insulin resistance do not stem
from a reduction in hepatic insulin extraction, but from an
enhancement in pancreatic insulin secretion that is
compensatory to reduced insulin sensitivity[12,34-36].
Fatty liver disease has been reported to be closely related
to indices of central obesity, such as waist circumference,
waist-to-hip ratio, and visceral fat thickness[5,35,37]. Central
obesity may contribute to insulin resistance, and increased
visceral adiposity might be relevant in the pathogenesis of
NAFLD[35,38]. Compared with adipose tissue in other sites,
visceral adipose tissue is more resistant to insulin, exhibits
greater lipolysis, and produces more free fatty acids[39]. The
increased availability of substrates for lipogenesis and the
relative hyperinsulinemia that accompany insulin resistance
promote lipogenesis in the liver[40]. Visceral adipose tissue is
also known to be a potent modulator of insulin action in
hepatic glucose production and gene expression[41]. However,
the significance of central obesity in the association between
liver steatosis and metabolic syndrome may differ by
ethnicity. It is well known that Asian people have lower
body mass indices and waist circumferences than do
Caucasians, but they have higher percent body fat and more
cardiovascular risk factors for a given level of obesity[42,43].
In further analysis, we found that the association between
liver steatosis and metabolic syndrome remained after
additional adjustments were made for waist circumference;
the odds ratios for mild, moderate, and severe steatosis
were 1.37, 2.39, and 2.72 for men (P for trend <0.001),
and 2.47, 2.57, and 3.27 for women (P for trend <0.001),
respectively. Moreover, we have already reported that
NAFLD was associated with various metabolic abnormalities
in non-obese non-diabetic subjects[15]. Further studies will
be required to investigate the ethnic and regional differences
in the relationship between liver steatosis and metabolic
syndrome.
Our study had several strengths. First, we showed an
association between the degree of severity of liver steatosis
detected by ultrasonography and the occurrence of metabolic
syndrome in apparently healthy subjects. The progressive
association between ultrasonographic liver steatosis and
common metabolic diseases had previously been observed
in data collected from patients, but had not yet been studied
in the general population. Second, we were able to diminish
the sources of  inter-observer measurement error, for the
liver ultrasonography in particular, because all of the
measurements were performed by the same examiner in
the same regulated setting, over a relatively short period
(3 mo). Third, we were able to assess the association between
metabolic syndrome and serum liver enzyme levels. Our
data suggest that liver ultrasonography may be a better
diagnostic tool than the determination of  serum enzyme
levels for monitoring liver function in people with metabolic
syndrome.
We should point out some of  the limitations of  the present
study. First, we could not assess the temporal relationship
between fatty liver disease and metabolic syndrome because
the study had a cross-sectional design. Although there is
increasing evidence indicating that NAFLD is a hepatic
consequence of metabolic syndrome [2,12,34,35], further
prospective studies should be conducted to examine the
temporal relationship between aminotransferase levels and
metabolic syndrome in the general population. Second, we
could not take into consideration any variation in the
metabolic profile over time because we obtained only one
measurement in each participant. Third, it is possible that
we did not control entirely for confounding effects caused
by viral and alcoholic liver diseases. We excluded subjects
who were positive for HBsAg from the analyses because
HBV infection is the most common liver disease in Korea,
but we could not rule out the effects of other types of viral
hepatitis. Alcoholic liver diseases are also common forms
of chronic liver disease, but, in a further analysis, the
association between liver steatosis and metabolic syndrome
was not significantly affected by the level of alcohol intake.
However, the possibility of residual confounding effects
still exists because we measured alcohol intake with a simple
questionnaire and did not use any objective index for alcohol
intake. Finally, the study participants were apparently healthy
members of the general population, but they were recruited
from within a health screening center. Therefore, our study
population was not necessarily representative of the general
Korean population.
In conclusion, the present study showed a strong positive
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association between the severity of ultrasonographic liver
steatosis and the prevalence of metabolic syndrome in
1 022 apparently healthy Koreans. Our findings indicate that
the degree of fatty infiltration detected on ultrasonography
can be used as an indicator of liver dysfunction attributable
to metabolic abnormalities. In addition, ultrasonography
may be a better diagnostic tool than serum enzyme assays
for monitoring liver function in people with metabolic
syndrome.
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